News >

FDA Grants Entrectinib Priority Review for NTRK+ Tumors and ROS1+ NSCLC

Gina Columbus @ginacolumbusonc
Published: Tuesday, Feb 19, 2019

Dr. Sandra Horning

Sandra Horning, MD
The FDA has granted a priority review designation to a new drug application (NDA) for entrectinib as a treatment for select adult and pediatric patients with NTRK fusion–positive locally advanced or metastatic solid tumors, as well as patients with metastatic ROS1-positive non–small cell lung cancer (NSCLC), according to Genentech, the developer of the multikinase inhibitor.1

UPDATE 8/15/2019: FDA Approves Entrectinib for NTRK+ Tumors and ROS1+ NSCLC

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication